Three patents currently held, every record listed here
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2043. from the record
Of the 5 now held by other companies, 5 were conveyed to Flagship Pioneering Innovations VI LLC in the filing they arrived in. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2043
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2024 to 2044.20282032203620402044
17 pending applications: term is not computable until grant.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- Nov 9Assignment recorded on 1 record: Root, Adam and 10 others to Generate Biomedicines, Inc. Recorded Nov 9, 2026, executed Mar 21, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76693, frame 540.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Image Generation with Flexible Sampler for Diffusion Modeling | 1 in force | to Jun 2044 |
| Diffusion Model for Generative Protein Design | 1 in force | to Nov 2043 |
| Antigen Binding Molecules Targeting SARS-CoV-2 | 1 in force | to May 2043 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,993,644 | Antigen Binding Molecules Targeting SARS-CoV-2 In force · High confidence | In force | High confidence | |
| US 12,580,040 | Diffusion Model for Generative Protein Design In force · Medium confidence | In force | Medium confidence | |
| US 12,579,706 | Image Generation with Flexible Sampler for Diffusion Modeling In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 5 patents in force now held by others · 17 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.